SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Joe Frazier

PatientJoe Frazier
Date of birth1962-01-12
IdentifiersMRN HR-BX004-SYN; SSN (made up) 000-04-5590
Document date2026-05-18
AuthorClarence Whitfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review: A1c, blood pressure, weight and semaglutide dose. [S]

History of Present Illness

Mr. Frazier returns five weeks after his eight-week review. He has taken semaglutide 0.5 mg weekly for seven weeks without nausea. He takes amlodipine 10 mg; home readings average 128/78, and he has no ankle swelling. He has had no alcohol. He has lost 4.1 kg since intake. He missed his eye clinic appointment because it fell on the evening of a fight card at his gym, and it has not yet been rebooked. [S]

ElementDetail
Semaglutide0.5 mg weekly for seven weeks; no side effects
Home blood pressureAverage 128/78 on amlodipine 10 mg
Weight99.9 kg, down 4.1 kg
Eye examinationMissed; not rebooked

Review of Systems

SystemResultFinding
EyesNegativeNo new blurring or floaters in the right eye
GastrointestinalNegativeNo nausea or abdominal pain
CardiovascularNegativeNo ankle swelling

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for yearsOne tablet twice daily with mealsOral route2026-02-16activeS
Lisinopril 20 mg oral tablet, one tablet daily; taken for yearsOne tablet dailyOral route2026-02-16activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-02-16activeS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-02 to 2026-04-13completedS
Amlodipine 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-04-13activeS
Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly0.25 mg weekly for four weeks, then 0.5 mg weeklySubcutaneous route2026-03-02 to 2026-05-18completedS
Semaglutide pen (1 mg per dose), 1 mg under the skin once weekly1 mg once weeklySubcutaneous route2026-05-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-18Body height182cmS
2026-05-18Body weight99.9kgS
2026-05-18Body mass index (BMI) [Ratio]30.2kg/m2S
2026-05-18Systolic blood pressure126mm[Hg]S
2026-05-18Diastolic blood pressure78mm[Hg]S
2026-05-18Heart rate74/minS
2026-05-18Respiratory rate16/minS
2026-05-18Body temperature36.6CelS
2026-05-18Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-18Hemoglobin A1c/Hemoglobin.total in Blood7.3%Below 5.7% is normal; goal below 7% for himHighS

Physical Exam

Vital signs recorded on 2026-05-18; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 126/78, pulse 74; weight 99.9 kg, BMI 30.2
CardiovascularNo ankle edema
AbdomenSoft; no ascites

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetesactiveconfirmed E11.65S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic.
Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressureactiveconfirmed I10S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life.
Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluatedresolvedconfirmed R74.01S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis.
Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcoholactiveconfirmed K76.0S — Synthetic modern diagnosis. Not part of the public record of his life; chosen to teach surveillance.
Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh Aactiveconfirmed K74.69S — Synthetic modern diagnosis. Not part of the public record of his life; the liver cancer diagnosed three years later in the true frame does not appear in the modern episode.
Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statinactiveconfirmed E78.5S — Synthetic laboratory finding.
Obesity, class 1 (BMI 31.4)activeconfirmed E66.811S — Synthetic finding; described without stigma.
Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30activeconfirmed H54.62S — Synthetic modern measurement anchored to the documented cataract in his left eye.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHemoglobin A1cEvery 3 months until at goal or after a change in treatment, then every 6 monthsCompleted today7.3% from 8.4%
ExaminationBlood pressure (clinic and home), weight and BMIEvery visitCompleted today126/78 in the clinic; home average 128/78; weight 99.9 kg
Medication safetySemaglutide dose steps, nausea, abdominal pain, gallbladder and pancreatitis symptomsAt each dose stepCompleted today0.5 mg for seven weeks without side effects; increased to 1 mg
Medication safetyLow blood sugar review and medicine tolerabilityEvery visitCompleted todayNo low blood sugar
ExaminationDilated eye examinationAt the start of care, then every 1 to 2 years; promptly when A1c is falling quickly on a GLP-1 receptor agonistDeferredPlanned at intake but not done three months later: he missed the appointment, and it was not rebooked. No harm is known: he has no new eye symptoms, and the later examination found no retinopathy. Corrective action: the clinic rebooked it on a day he chose, with a reminder call, before the A1c falls further
LaboratoryPotassium, creatinine and eGFR (CKD-EPI 2021) on lisinoprilEvery 6 months on an ACE inhibitor, and after changesUp to dateStable five weeks ago; next at seven months
ImagingLiver ultrasound with AFP for hepatocellular carcinoma surveillanceEvery 6 months in cirrhosisUp to dateNext in September
Self-managementWeight loss of 7 to 10%Each visitCompleted today4% so far
Self-managementAlcohol abstinenceEvery visitCompleted todayNo alcohol
Self-managementDiabetes self-management educationAt the start of care and yearlyCompleted todaySeries of classes completed

Goal progress:

Guideline basis: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026)

Follow-up: Eye clinic next month. Preventive visit in eight weeks. Seven-month review in September with the surveillance ultrasound and AFP. Next scheduled visit 2026-07-13: periodic adult preventive visit. [S]